


## PHARMACEUTICAL 2017



## CUMBERLAND PHARMACEUTICALS SELECTION INC

Rank 30 of 313





## PHARMACEUTICAL 2017



## CUMBERLAND PHARMACEUTICALS \$\frac{1}{2} \text{PHARMACEUTICALS}\$ **INC**



Rank 30 of 313

The relative strengths and weaknesses of CUMBERLAND PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CUMBERLAND PHARMACEUTICALS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 279% points. The greatest weakness of CUMBERLAND PHARMACEUTICALS INC is the variable Other Expenses, reducing the Economic Capital Ratio by 105% points.

The company's Economic Capital Ratio, given in the ranking table, is 134%, being 551% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	65,545
Cost of Goods Sold	0
Intangible Assets	22,154
Liabilities, Current	14,792
Liabilities, Non-Current	1,391
Other Assets	5,241
Other Compr. Net Income	0
Other Expenses	22,482
Other Liabilities	4,100
Other Net Income	205
Property and Equipment	464
Research and Development	3,191
Revenues	33,026
Selling, General and Administrative Expense	8,562

Output Variable	Value in 1000 USD
Assets	93,405
Liabilities	20,284
Expenses	34,234
Stockholders Equity	73,121
Net Income	-1,004
Comprehensive Net Income	-1,004
Economic Capital Ratio	134%